Romiplostim
- 1 November 2008
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 7 (11) , 887-888
- https://doi.org/10.1038/nrd2741
Abstract
In August 2008, romiplostim (Nplate; Amgen), a thrombopoietin receptor agonist, was approved by the US FDA for the treatment of thrombocytopaenia in patients with chronic immune thrombocytopaenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.Keywords
This publication has 16 references indexed in Scilit:
- Diamonds, Development, and DemocracyWorld Policy Journal, 2008
- Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 studyBlood, 2008
- Historical review: megakaryopoiesis and thrombopoiesisBlood, 2008
- Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialThe Lancet, 2008
- Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 2007
- Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis CNew England Journal of Medicine, 2007
- AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITPNew England Journal of Medicine, 2006
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Immune Thrombocytopenic PurpuraNew England Journal of Medicine, 2002
- Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.Journal of Clinical Investigation, 1987